Importance Early treatment initiation in multiple sclerosis (MS) is crucial in preventing
irreversible neurological damage and disability progression. The current assessment of …

Spinal muscular atrophy is a devastating motor neuron disease characterized by severe
cases of fatal muscle weakness. It is one of the most common genetic causes of mortality …

Abstract Objectives Neurofilament light chain (NfL) is an emerging biomarker of
neurodegeneration disorders. Knowledge of the biological variation (BV) can facilitate …

Background: Serum neurofilament light (sNfL) reflects neuroaxonal damage and is now
used as an outcome in treatment trials of relapsing-remitting multiple sclerosis (RRMS) …

Neurofilament light protein (NfL) is a part of the neuronal skeleton, primarily expressed in
axons, and is released when nerves are damaged. NfL has been found to be a potential …

Introduction Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease that
represents a leading cause of non-traumatic disability among young and middle-aged …

Background: Resistance training (RT) has been recognized as a beneficial non-
pharmacological intervention for multiple sclerosis (MS) patients, but its impact on …

Background Studies have demonstrated that people with multiple sclerosis (MS) experience
visual impairments and neurodegenerative retinal processes. The disability progression in …

Background In the field of research for new validated surrogate biomarkers of treatment
efficacy, disease activity and progression in Multiple Sclerosis (MS), serum neurofilament …

Fluid biomarkers such as Glial Fibrillary Acidic Protein (GFAP) and Neurofilament Light (NfL)
play important roles in the diagnosis, monitoring, and evaluation of therapeutic responses in …